XTL Biopharmaceuticals Ltd. - (XTLB) share price
XTL Biopharmaceuticals Ltd. - (NASDAQ:XTLB) last traded at $1.55, down 9.76% on the day (quote 2026-11-06 21:00 UTC), with a market cap of $0.00B and a 52-week range of $1.55 to $5.64.
| Exchange | NASDAQ |
|---|---|
| Currency | USD |
| Last price | $1.55 |
| 1-day move | -9.76% |
| 52-week range | $1.55 - $5.64 |
| Market cap | $0.00B |
| From 52-week high | -72.50% |
| Volume vs average | 0.5x |
| Falling Shares risk score | 77/100 (CRITICAL) |
| Country | United States |
Frequently asked questions
Why is XTL Biopharmaceuticals Ltd. - falling today?
XTL Biopharmaceuticals Ltd. - (NASDAQ:XTLB) is down 9.76% at its latest quote and trades 72.5% below its 52-week high, at a new 52-week low. A price fall alone does not identify a cause: Falling Shares Intelligence links a move to a filing, order or news item only when a source supports it.
What is the XTL Biopharmaceuticals Ltd. - share price today?
XTL Biopharmaceuticals Ltd. - (NASDAQ:XTLB) last traded at $1.55, a -9.76% move on the day as of 2026-11-06 21:00 UTC. Market data comes from public feeds and may be delayed; it is not investment advice.
What is the 52-week range of XTL Biopharmaceuticals Ltd. -?
XTL Biopharmaceuticals Ltd. -'s 52-week low is $1.55 and its 52-week high is $5.64; the shares trade 72.5% below the high.
What is the market cap of XTL Biopharmaceuticals Ltd. -?
XTL Biopharmaceuticals Ltd. - has a market capitalisation of about $0.00B at the latest price.
What are the risks of investing in XTL Biopharmaceuticals Ltd. -?
Falling Shares Intelligence rates XTL Biopharmaceuticals Ltd. - 77/100 (CRITICAL) on price stress, volume and disclosure signals. Risk scores are analytical indicators, not allegations or investment advice. Review exchange filings and the company's own disclosures before any decision.
Data is compiled from public exchange feeds and may be delayed. Not investment advice.
Wung Thomas, Editor-in-Chief: wungthomas@fallingshares.com. General enquiries and corrections: info@fallingshares.com